A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE

Condition:   Hepatocellular Carcinoma (HCC) Interventions:   Drug: Durvalumab;   Drug: Bevacizumab;   Procedure: Transarterial Radioembolization (TARE) Sponsor:   AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials